OMDA vs VKTX
OMDA: Virtual care platform combining human health coaches and AI-driven technology to deliver preventive and chronic disease management programs for cardiometabolic conditions, obesity, and musculoskeletal health at scale. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | OMDA | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.84 | $37.31 | |
| Market cap as of 2026-07-23 | $1.3B | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -2.2% | n/a | |
| Gross margin as of 2026-07-23 | +66.3% | n/a | |
| Operating margin as of 2026-07-23 | -3.7% | n/a | |
| ROE as of 2026-07-23 | -2.8% | -71.3% | OMDA higher |
| ROA as of 2026-07-23 | -2.1% | -65.3% | OMDA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +42.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +45.6% | n/a | |
| Beta as of 2026-07-23 | 1.33 | 0.65 | |
| 1-year return as of 2026-07-22 close | +13.6% | +16.2% | VKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.